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CC BY-NC-ND license (http://creativeBackground: Slowly resolving pneumonia (SRP) poses early challenges for identification and
medical expense for clinicians in intensive care units (ICUs); to date, the literature has been
very limited in this regard.
Methods: This was a retrospective and cohort-based study in the ICU of a university-affiliated
hospital in Shanghai. Medical records of pneumonia patients in the ICU between April 2008 and
February 2011were reviewed retrospectively to evaluate the risk factors for SRP.
Results: In all, 106 pneumonia patients in the ICU were identified as immune-competent with a
diagnosis of bacterial pneumonia. There were 62 (58.49%) patients who showed SRP and their
radiographic infiltrations were completely resolved between 5 weeks and 8 weeks. Multivariate
logistic regression analysis demonstrated that initial treatment with an inappropriate antibi-
otic, multilobar infiltration, and a high CURB-65 score were independent risk factors for SRP,
with odds ratio (OR) values of 8.338 [95% confidence interval (CI) 2.117e32.848], 11.184
(95% CI 2.526e49.514), and 2.329 (95% CI 1.172e4.626), respectively. The length of the ICU
stay in the SRP group was twice as long as that of the normally resolving pneumonia (NRP)
group (62.27  73.73 vs. 32.25  23, p Z 0.002). The 28-day and 60-day mortality rates in
the SRP group were 17.74% and 25.81%, respectively. In addition, the 60-day mortality rate
was significantly higher in the SRP group than the NRP group (25.81% vs. 6.82%, respectively;
p Z 0.012). Moreover, SRP was an independent risk factor for 60-day mortality (OR 5.687,
95% CI 1.334e24.240).of Critical Care Medicine and Respiratory Intensive Care Unit, Ruijin Hospital, Shanghai Jiao Tong
i-Jin Er Road, Boulevard 36, Shanghai 200025, China.
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Risk factors for slowly resolving pneumonia in the ICU 655Conclusion: Treatment with an inappropriate antibiotic, multilobar infiltration, and a high
CURB-65 score were independent risk factors for SRP.
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The unapparent resolution of pulmonary infiltrates in both
nonresolving and slowly resolving pneumonia (SRP) poses
diagnostic and treatment challenges for clinicians as a
common consultation problem.1,2 Nonresolving pneumonia
often represents a noninfectious process that mimics an
infectious process.3,4 SRP is usually associated with host- or
treatment-related factors.5,6 Advances in procedures used
to diagnose pneumonia have led to a declining incidence of
nonresolving pneumonia, while the incidence of SRP is
definitely rising with multiple supporting methods.7,8 Kirt-
land and Winterbauer9 first proposed a definition of SRP
that referred to immune-competent patients who exhibited
improved clinical symptoms with antibiotic therapy and
chest radiographs with less than 50% clearing by 2 weeks or
less than complete clearing at 4 weeks.10 To date, the
literature concerning the evaluation and treatment of SRP
has been limited. Although the precise incidence of SRP is
not well established, early studies reported that 25e67% of
the pulmonary infiltration of pneumonia patients showed
delayed resolution along with high mortality,11 prolonged
hospital stays, and high treatment costs.8 Some studies on
critically ill patients found that as many as 47% of pneu-
monia cases showed delayed resolution.12 Due to its high
incidence and poor outcome, the recognition and resolution
of SRP in intensive care units (ICUs) deserve more attention
from clinicians.
The objective of this study was to investigate the inci-
dence, length of ICU stay, outcome, and risk factors asso-
ciated with SRP in critically ill patients to promote the
identification of high-risk patients.
Methods
Ethical statement
The extent of our involvement with participants was
limited to the evaluation of radiographic resolution and
analysis of the participants’ clinical features. We promised
to hold all the information of participants in a confidential
manner. The study protocol and consent procedure with
waiver of written consent was approved by the Shanghai
Jiao Tong University School of Medicine and affiliated to the
Ruijin Hospital Ethics Committee.
Study population
The study group was sampled from patients who were
admitted to the ICU of a 1300-bed university-affiliated hos-
pital with a diagnosis of pneumonia between April 2008 and
February 2011. {Pneumonia was defined as a new orprogressive infiltrate as seen on a chest radiograph or
computed tomography (CT) scan along with a high clinical
suspicion of pneumonia, defined by at least one of the
following: fever (>38C); leucopenia [< 4000 white blood
cells (WBC)/mm3] or leukocytosis (> 12,000 WBC/mm3);
altered mental status with no other recognized cause (for
adults older than 70 years); and at least two of the following:
(a) new onset of purulent sputum, change in characteristics
of sputum, increased respiratory secretions, or increased
suctioning requirements, (b) new onset or worsening cough,
dyspnea, or increased ventilation demand.}
The inclusion criteria included pneumonia patients who
reached clinical stability due to treatment in the ICU with a
complete resolution or resolution of infiltrate differenti-
ated from chronic changes. [Clinical stability was defined as
a temperature  37.8C, a heart rate  100 beats/min, a
respiratory rate  24 breaths/min, systolic blood pressure
 90 mmHg, arterial oxygen saturation  90% or
PaO2  60 mmHg in room air, the ability to maintain oral
intake, and a normal mental status.10]
The exclusion criteria included patients with immunode-
pression, interstitial pneumonia, pulmonary tumor, pulmo-
nary tuberculosis, influenza A virus subtype H1N1 or another
respiratory tract virus, legionnaires pneumonia, mycoplasma
pneumonia, chlamydia pneumonia, and acute respiratory
distress syndrome. [Immunodepression was defined as a
recent history of neutropenia (< 0.5  109 neutrophils/L for
110 days); the receipt of an allogeneic stem cell transplant;
the prolonged use of corticosteroids (a mean minimum dose
of 0.3 mg of prednisone equivalent/kg/day for 13 weeks);
treatment with another recognized Tcell suppressant such as
cyclosporine, tumor necrosis factor-alpha (TNF-a) blockers,
specific monoclonal antibodies, or nucleoside analogs during
the past 90 days; or inherited severe immunodeficiency (such
as chronic granulomatous disease or severe combined
immunodeficiency).13]
Study methodology
Every eligible patient had pre-pneumonia radiography as
basic radiographic data and a CT scan performed to identify
pulmonary destruction and multilobar infiltration. Each
pneumonia patient was evaluated once a week in the ICU
by bedside X-ray examination or CT scan if possible until the
pulmonary infiltrates were completely resolved or their
radiological signs normalized to previous levels. Two
specialized radiography colleagues who were blinded to
clinical status evaluated the radiographic infiltrates. The
patients with SRP reached clinical stability but exhibited
either persistent pulmonary infiltrates 4 weeks after an
initial pneumonia-like syndrome or demonstrated less than
50% clearing on chest radiographs taken 2 weeks after
starting antibiotic therapy. The normally resolving
Figure 1. The complete radiographic resolution time for the
two groups. The green line shows that the radiographic infil-
tration in the normally resolving pneumonia (NRP) patients
completely resolved within 4 weeks, while the slowly resolving
pneumonia (SRP) patients (blue line) required 5e8 weeks for
complete resolution.
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normalized to previous levels within 4 weeks.
In our ICU, we usually did the sputum or endotracheal
aspiration culture weekly or twice a week if needed as a
routine procedure. Each pneumonia patient was examined
for Mycobacterium tuberculosis, influenza virus, or other
atypical pathogen to rule out pulmonary tuberculosis (TB),
H1N1, or other atypical pneumonia. We also performed a
Gram stain on sputum or endotracheal aspiration, and
measured procalcitonin (PCT) and C-reactive protein (CRP)
to identify colonization or infection.
Data collection
We collected clinical data from the participants, including
their sex, age, aspiration history, pulmonary radiography,
underlying diseases, CURB-65 score (a severity score including
confusion, uremia, respiratory rate, blood pressure and age),
Acute Physiology And Chronic Health Evaluation (APACHE) II
score, PCT level, CRP level, microorganism from sputum
sample or endotracheal aspiration, antibiotic susceptibility
test, anti-infection treatments, steroid applications, need for
an artificial airway, time required for radiographic clearing,
and 28-day and 60-day mortality rates.
Definitions of risk factors
Initial treatment with an inappropriate antibiotic was defined
as the first administration of an antimicrobial agent to which
at least one causativemicroorganismwas resistant or the lack
ofantimicrobial therapy for a knowncausativepathogen.14e16
High-dose steroid application was defined as the appli-
cation of more than 2 mg intravenous methylprednisolone/
kg/day for at least 14 days.17,18
The continued isolation of pathogen was defined as the
elimination of the original pathogen from sputum cultures
less than twice.19
Delayed clinical stability referred to a pneumonia pa-
tient who required more than 6 days to reach clinical
stability.10
Statistical analysis
SPSS software (version 17.0; SPSS Inc., Chicago, IL, USA)
was used for data analysis. The qualitative variables were
expressed as frequency (%), while the quantitative vari-
ables were expressed as the mean  standard deviation
(SD). The SRP group was compared with the NRP group using
the c2 test, the continuity correction c2 inspection, or
Fisher’s exact test for the qualitative variables (sex, type of
pneumonia, aspiration history, radiographic characteris-
tics, underlying diseases, microorganism and antibiotic
susceptibility test results, anti-infection treatments, ste-
roid applications, need for an artificial airway, 28-day and
60-day mortality rates) and a t test for the quantitative
variables (age, CURB-65 score, APACHE II score, PCT level,
CRP level). The data without a normal distribution were
analyzed by the rank sum test. Univariate and multivariate
analyses were performed to determine the risk factors
associated with SRP. The KaplaneMeier method was used
for the survival function.Results
Characteristics of the patients
There were 154 pneumonia patients admitted to the ICU
between April 2008 and February 2011. A total of 106
pneumonia patients were eligible for inclusion in the study,
and 62 pneumonia patients met the criteria for SRP, exhib-
iting radiographic infiltration that was completely resolved
within 5e8 weeks. The incidence of SRP was 58.49% (Fig. 1).
As part of our study methodology, we ruled out two cases of
pulmonary tuberculosis and five cases of H1N1 influenza. We
found that 90.9% of single-lobe pneumonia cases completely
resolve in 4 weeks, while 56% of multilobar pneumonia cases
required 5e8 weeks to completely resolve.
The demographic data including age, sex, and underlying
diseases were equivalent for both the SRP group (n Z 62)
and the NRP group (n Z 44). There were no differences in
aspiration history (n Z 28) and mechanical ventilation
(n Z 49) between the two groups. The radiographic study
revealed no significant differences in the destruction of the
pulmonary structure and pleural effusion between the two
groups (Table 1). The PCT level (2.08  3.74 vs. 0.86  1.42,
pZ 0.040) and the CRP level (8.75  10.65 vs. 5.49  5.54,
pZ 0.074) at admission were statistically higher in the SRP
group than that in the NRP group.
SRP group risk factors
A correlation analysis between quantitative variables such
as age, the number of underlying diseases, PCT, CRP, the
Table 1 The baseline characteristics of the patients
Characteristics Total (n Z 106) SRP (n Z 62) NRP (n Z 44) p
Agea 70.56  12.60 70.16  12.97 68.78  13.72 0.588
Sex: male/female 64/42 34/28 30/14 0.1664
Underlying disease
Heart failureb 35 (32.7%) 24 (38.71%) 11 (25.00%) 0.1392
Chronic obstructive pulmonary diseaseb 26 (24.3%) 16 (25.81%) 10 (22.73%) 0.7166
Central nervous system diseaseb 30 (28.0%) 19 (30.65%) 11 (25.00%) 0.5249
Diabetes mellitusb 20 (18.7%) 15 (24.19%) 5 (11.36%) 0.0962
Renal insufficiencyb 18 (16.98%) 13 (20.97%) 5 (11.36%) 0.1944
Hepatic insufficiencyb 10 (9.43%) 8 (12.90%) 2 (4.55%) 0.2656
Radiographic feature
Multilobar infiltrationb 34 (32.08%) 31 (50.00%) 4 (9.09%) < 0.0001
Pleural effusionb 52 (49.06%) 33 (53.23%) 19 (43.18%) 0.3081
Destruction of pulmonary structureb 40 (37.74%) 21 (33.87%) 19 (43.18%) 0.3298
Biomarker
PCTa 2.08  3.74 0.86  1.42 0.040
CRPa 8.75  10.65 5.49  5.54 0.074
a Values are given as the mean  standard deviation (SD).
b Values are given as number (%).
CRP Z C-reactive protein; NRP Z normally resolving pneumonia; PCT Z procalcitonin; SRP Z slowly resolving pneumonia.
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graphic resolution time was performed. This analysis
showed that the CURB-65 and APACHE II scores correlated
with the radiographic resolution time. The correlation co-
efficients for the CURB-65 and APACHE II scores were 0.2432
(p Z 0.012) and 0.2259 (p Z 0.0199), respectively. The
qualitative variables, which included central nervous sys-
tem disease, chronic obstructive pulmonary disease, heart
failure, diabetes mellitus, aspiration history, pulmonary
structure, pleural effusion, multilobar infiltration, initial
treatment with an inappropriate antibiotic, delayed clinical
stability, continued isolation of pathogen, multidrug-
resistant bacteria, artificial airway, and the application of
high-dose steroids, were statistically analyzed by a uni-
variate analysis. The univariate analysis identified treat-
ment with an inappropriate antibiotic, multilobar
infiltration, the lack of microbiological eradication,
delayed clinical stability, and the application of high-dose
corticosteroids as risk factors for SRP (Table 2).Table 2 Risk factors for slowly resolving pneumonia
(SRP), as identified by univariate analysis
Risk factor p RR value 95% CI
Inappropriate initial
antibiotic therapy
0.0004 1.7940 1.3639 2.3598
Multilobar infiltration < 0.0001 2.0286 1.5182 2.7105
Continued isolation
of pathogen
0.0443 1.3846 1.0097 1.8988
Delayed clinical
stability
0.0104 1.5553 1.0848 2.2298
High-dose
corticosteroid
application
0.0053 1.8462 1.5359 2.2191
CI Z confidence interval; RR Z relative risk.The microbiology results and initial antibiotic use of all
patients were summarized in Table 3. There was no dif-
ference in the culture-negative rates between SRP and NRP
groups (14.52% vs. 25%, p Z 0.17). There were no statisti-
cally significant differences in the bacterial species and
drug susceptibility testing present in the SRP and NRP
groups; however, multidrug-resistant bacteria appeared at
a higher rate in the SRP group (59.09%).The incidence of
inappropriate initial antibiotic use in the entire study
population was 27.36%dthis was evident by the value in
the SRP group that was fourfold higher than that of the NRP
group (p Z 0.0004). The multivariate logistic regression
analysis demonstrated that treatment with an inappro-
priate antibiotic, multilobar infiltration, and high CURB-65
score were independent risk factors for SRP (Table 4).
Prognosis and survey
The length of the ICU stay for the SRP group was twofold
longer than that of the NRP group (62.27  73.73 vs.
32.25  23, p Z 0.002). The 28-day and 60-day mortality
rates in the SRP group were 17.74% and 25.81%, respec-
tively. In addition, the 60-day mortality rate was signifi-
cantly higher in the SRP group than the NRP group (25.81%
vs. 6.82%, respectively; p Z 0.012) (Fig. 2). The multivar-
iate logistic regression analysis showed that SRP was an
independent risk factor for 60-day mortality [odds ratio
(OR) 5.687, 95% confidence interval (CI) 1.334e24.240].
Discussion
SRP exhibits a high incidence in critically ill patients and
causes prolonged ICU stays and expensive medical costs.
Our study showed that the presence of SRP is an indepen-
dent risk factor for 60-day mortality in the ICU. It is unlikely
that this definition could be used clinically to diagnose
Table 3 The microbiology results of all patients
No. Group Pathogena Culture site Initial antibiotics Inappropriate
initial
antibiotic use
1 SRP Acinetobacter baumannii Sputum Imipenem/cilastatin sodium N
2 SRP Acinetobacter baumannii (MDR) Tracheal aspirate Cefoperazone/sulbactam, minocycline N
3 SRP MRSA Sputum Cefepime Y
4 SRP Acinetobacter baumannii (PDR) Tracheal aspirate Linezolid, ceftriaxone Y
5 SRP Negative Tracheal aspirate Piperacillin/tazobactam N
6 SRP Staphylococcus epidermidis Tracheal aspirate Imipenem/cilastatin sodium Y
7 SRP Enterobacteria Tracheal aspirate Imipenem/cilastatin sodium N
8 SRP Klebsiella pneumoniae Sputum Piperacillin/tazobactam N
9 SRP Escherichia coli (ESBL) Sputum Levofloxacin Y
10 SRP Enterobacter cloacae Tracheal aspirate Vancomycin Y
11 SRP Flavobacterium indologenes Tracheal aspirate Piperacillin/tazobactam N
12 SRP Escherichia coli Tracheal aspirate Imipenem/cilastatin sodium N
13 SRP MRSA Sputum Linezolid N
14 SRP MSSA Tracheal aspirate Cefoperazone/sulbactam Y
15 SRP MRSA Tracheal aspirate Moxifloxacin Y
16 SRP Acinetobacter baumannii Sputum Imipenem/cilastatin sodium N
17 SRP Acinetobacter baumannii Tracheal aspirate Imipenem/cilastatin sodium N
18 SRP Staphylococcus capitis Tracheal aspirate Imipenem/cilastatin sodium Y
19 SRP Negative Sputum Imipenem/cilastatin, fucidin N
20 SRP Klebsiella pneumoniae Sputum Imipenem/cilastatin sodium N
21 SRP Acinetobacter baumannii Tracheal aspirate Cefoperazone/sulbactam, minocycline N
22 SRP Acinetobacter baumannii (MDR) Tracheal aspirate Teicoplanin Y
23 SRP Negative Tracheal aspirate Piperacillin/tazobactam N
24 SRP MRSA Tracheal aspirate Piperacillin/tazobactam Y
25 SRP Pseudomonas aeruginosa Tracheal aspirate Meropenem N
26 SRP MRSA Tracheal aspirate Imipenem/cilastatin sodium Y
27 SRP Negative Sputum Imipenem/cilastatin sodium N
28 SRP Klebsiella pneumoniae Tracheal aspirate Imipenem/cilastatin sodium N
29 SRP Acinetobacter baumannii Sputum Levofloxacin Y
30 SRP Acinetobacter baumannii (MDR) Tracheal aspirate Clindamycinum Y
31 SRP MRSA Tracheal aspirate Vancomycin N
32 SRP Pseudomonas aeruginosa (MDR) Tracheal aspirate Cefepime N
33 SRP Acinetobacter baumannii Sputum Meropenem N
34 SRP Acinetobacter baumannii Tracheal aspirate Imipenem/cilastatin sodium N
35 SRP Negative Tracheal aspirate Imipenem/cilastatin sodium N
36 SRP Acinetobacter baumannii Tracheal aspirate Imipenem/cilastatin sodium N
37 SRP Burkholderia cepacia Tracheal aspirate Vancomycin Y
38 SRP Acinetobacter baumannii (PDR) Tracheal aspirate Meropenem, linezolid Y
39 SRP Acinetobacter baumannii (PDR) Sputum Imipenem/cilastatin sodium N
40 SRP Enterococcus faecalis Sputum Imipenem/cilastatin sodium Y
41 SRP Klebsiella pneumoniae Tracheal aspirate Imipenem/cilastatin sodium N
42 SRP Negative Sputum Imipenem/cilastatin sodium, teicoplanin N
43 SRP Acinetobacter baumannii (MDR) Sputum Azithromycin Y
44 SRP Pseudomonas aeruginosa Sputum Imipenem/cilastatin sodium N
45 SRP Acinetobacter baumannii (PDR) Sputum Azithromycin Y
46 SRP Klebsiella pneumoniae Sputum Imipenem/cilastatin sodium N
47 SRP Acinetobacter baumannii (PDR) Sputum Cefuroxime Y
48 SRP Acinetobacter baumannii Sputum Imipenem/cilastatin sodium N
49 SRP Acinetobacter baumannii Tracheal aspirate Levofloxacin Y
50 SRP Acinetobacter baumannii Tracheal aspirate Levofloxacin Y
51 SRP Enterococcus faecium Sputum Vancomycin N
52 SRP Acinetobacter baumannii Sputum Levofloxacin Y
53 SRP Negative Tracheal aspirate Imipenem/cilastatin sodium, vancomycin N
54 SRP MRSA Sputum Ceftazidime Y
55 SRP Klebsiella pneumoniae (ESBL) Sputum Cefoxitin Y
56 SRP Klebsiella pneumoniae Sputum Imipenem/cilastatin sodium N
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Table 3 (continued )
No. Group Pathogena Culture site Initial antibiotics Inappropriate
initial
antibiotic use
57 SRP Acinetobacter baumannii (PDR) Tracheal aspirate Cefoxitin Y
58 SRP Negative Sputum Imipenem/cilastatin sodium, vancomycin N
59 SRP Acinetobacter baumannii Sputum Imipenem/cilastatin sodium N
60 SRP Negative Sputum Imipenem/cilastatin sodium N
61 SRP Acinetobacter baumannii (MDR) Sputum Moxifloxacin Y
62 SRP Staphylococcus epidermidis Sputum Vancomycin N
1 NRP Acinetobacter baumannii Sputum Ceftazidime N
2 NRP Acinetobacter baumannii Tracheal aspirate Imipenem/cilastatin sodium N
3 NRP Pseudomonas aeruginosa Sputum Imipenem/cilastatin sodium N
4 NRP Acinetobacter junii Sputum Piperacillin/tazobactam, minocycline N
5 NRP Negative Sputum Ceftazidime N
6 NRP Klebsiella pneumoniae Sputum Meropenem N
7 NRP MRSA Sputum Vancomycin N
8 NRP Staphylococcus epidermidis Sputum Vancomycin N
9 NRP Acinetobacter baumannii (MDR) Sputum Cefoperazone/sulbactam, minocycline N
10 NRP Negative Tracheal aspirate Piperacillin/tazobactam N
11 NRP MRSA Tracheal aspirate Vancomycin N
12 NRP Negative Sputum Piperacillin/tazobactam N
13 NRP Negative Tracheal aspirate Meropenem, teicoplanin N
14 NRP Enterococcus faecium Tracheal aspirate Vancomycin N
15 NRP Negative Sputum Piperacillin/tazobactam N
16 NRP Acinetobacter baumannii Tracheal aspirate Cefoperazone/sulbactam N
17 NRP MRSA Tracheal aspirate Vancomycin N
18 NRP Acinetobacter baumannii (MDR) Sputum Levofloxacin Y
19 NRP Acinetobacter baumannii Sputum Ceftazidime N
20 NRP Negative Tracheal aspirate Imipenem/cilastatin sodium N
21 NRP Acinetobacter baumannii Tracheal aspirate Imipenem/cilastatin sodium N
22 NRP Pseudomonas aeruginosa Sputum Ceftazidime N
23 NRP Acinetobacter baumannii Sputum Cefoperazone/sulbactam, minocycline N
24 NRP Pseudomonas aeruginosa Tracheal aspirate Cefoperazone/sulbactam N
25 NRP Enterobacter aerogenes Sputum Cefoxitin N
26 NRP Acinetobacter baumannii Tracheal aspirate Cefoperazone/sulbactam N
27 NRP Staphylococcus aureus Sputum Vancomycin N
28 NRP Klebsiella pneumoniae Sputum Clindamycin Y
29 NRP Negative Tracheal aspirate Maxipime N
30 NRP Acinetobacter junii Sputum Piperacillin/tazobactam N
31 NRP Negative Sputum Meropenem, teicoplanin N
32 NRP Acinetobacter baumannii (PDR) Tracheal aspirate Imipenem/cilastatin sodium N
33 NRP Negative Sputum Piperacillin/tazobactam N
34 NRP Acinetobacter baumannii (PDR) Tracheal aspirate Vancomycin Y
35 NRP Burkholderia cepacia Tracheal aspirate Cefoperazone N
36 NRP Klebsiella pneumoniae (ESBL) Tracheal aspirate Meropenem N
37 NRP Klebsiella pneumoniae Sputum Ceftazidime N
38 NRP Enterococcus faecalis Sputum Vancomycin N
39 NRP Negative Sputum Ceftazidime N
40 NRP Burkholderia cepacia Sputum Ceftazidime N
41 NRP Klebsiella pneumoniae Tracheal aspirate Ceftazidime N
42 NRP Negative Sputum Moxifloxacin N
43 NRP Staphylococcus epidermidis Sputum Teicoplanin N
44 NRP Enterobacter cloacae Sputum Ceftazidime N
a Pathogens were yielded from a sputum sample or endotracheal aspiration. A second appropriate antibiotic was used in individual
patients according to their microorganism results.
ESBL Z extended-spectrum b-lactamases; MDR Z multiple drug resistance; MRSA Z methicillin-resistant Staphylococcus aureus;
MSSA Z methicillin-sensitive Staphylococcus aureus; N Z no; NRP Z normally resolving pneumonia; PDR Z pandrug-resistant;
SRP Z slowly resolving pneumonia; Y Z yes.
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Table 4 Independent risk factors for slowly resolving
pneumonia (SRP)
Risk factor p OR 95% CI
Inappropriate initial
antibiotic therapy
0.0024 8.338 2.117 32.848
Multilobar infiltration 0.0015 11.184 2.526 49.514
CURB-65 score 0.0158 2.329 1.172 4.626
Delayed clinical stability 0.3131 1.775 0.582 5.414
CI Z confidence interval; OR Z odds ratio.
660 M. Li et al.patients with SRP at an early time point. Therefore, further
investigation is required to identify the risk factors for SRP
for early identification. From a list of possible factors
including host-related factors, pulmonary radiographic
features, microorganism characteristics, and treatment-
related factors,8,11,20,21 our study suggested that the extent
of pulmonary infiltration, pneumonia severity, and initial
antibiotic therapy have important effects on the resolution
of pneumonia in critically ill patients.
We found that 90.9% of single-lobe pneumonia cases
completely resolve in 4 weeks, while 56% of multilobar
pneumonia cases require 5e8 weeks to completely resolve
as demonstrated in a Pneumococcus pneumonia study.22
However, several previous studies in heterogeneousFigure 2. The survival functions of the two groups. The 28-
day mortality rate was higher in the slowly resolving pneu-
monia (SRP) group than the normally resolving pneumonia
(NRP) group, but this difference was not statistically significant
(p Z 0.10). By contrast, the 60-day mortality rate was signif-
icantly higher in the SRP group than the NRP group (pZ 0.02).
The gap between the two lines illustrates the relationship
between the length of the intensive care unit (ICU) stay and
the mortality rate in the two groups.populations have suggested that the extent of pulmonary
infiltration has an impact on pneumonia resolution.22,23 In
critically ill patients, our study showed that the incidence
of multilobar infiltration is much higher in the SRP group
than the NRP group and is an independent risk factor for
SRP. Therefore, we recommend that pneumonia cases in
the ICU receive an immediate radiographic evaluation to
determine the extent of infiltration and assess the possi-
bility of SRP.
Both the extent of pulmonary infiltration and pneumonia
severity had an impact on SRP. Several disease severity
indicators are used in the ICU, including CURB-65 scores,24
APACHE II scores, and biomarkers such as PCT and CRP.
Current studies suggest that advanced age, a fast respira-
tory rate, low blood pressure, and underlying diseases are
risk factors for SRP.21 The CURB-65 score is a synthetic
index that includes age, confusion, uremia, respiratory
rate, and blood pressure. Our study showed that the CURB-
65 score instead of the APACHE II score was not only posi-
tively correlated with pneumonia resolution time but also
an independent risk factor for SRP.
Some studies suggested that PCT and CRP levels could
indicate pneumonia severity.25,26 One study showed that a
high CRP level was independently associated with the
delayed resolution of radiographic abnormalities,12 while
Huang et al26 showed that the PCT level provided little
additional information over the CURB-65 score. Our results
reflected no differences in the CRP levels of the SRP and
NRP groups, whereas the PCT level was higher in the SRP
group. However, our study further suggested that the CURB-
65 score alone was an independent risk factor for SRP as a
pneumonia severity indicator.
SRP was associated with both host-related factors and
treatment-related factors. Treatment with an appropriate
antibiotic plays an important role in pneumonia resolu-
tion.19,27 A few reports have shown that the incidence of
inappropriate antibiotic therapy was high in pneumonia
patients, especially in ventilator-associated pneumonia
patients (50%) in the ICU.28 We found the incidence of
inappropriate initial antibiotic use in the entire study
population to be 27.36%, as shown by the fact that the
value in the SRP group was fourfold higher than that of the
NRP group (p Z 0.0004). Initial treatment with an inap-
propriate antibiotic was independently associated with SRP,
with the OR value for this variable adjusted to 8.338 by
multivariate logistic regression analysis (Table 3).
Treatment with an inappropriate antibiotic is very
important because it is the only SRP risk factor that can be
modified to reduce SRP and improve patient outcomes.29
The initial selection of an antimicrobial regimen for pneu-
monia must be guided by consideration of the local mi-
crobial ecology and the type of pneumonia to ensure
effective antibiotic therapy.30 There were no differences in
the bacterial species and drug susceptibility testing present
in the SRP and NRP groups; however, multiple drug resis-
tance (MDR) bacteria appeared at a higher rate in the SRP
group (59.09%). Some studies have suggested that both the
bacterial species and possible drug resistance should be
taken into account when choosing the antibiotic therapy for
patients who are likely to be infected with MDR pathogens
(including methicillin-resistant Staphylococcus aureus,
MRSA).31,32 It is better to identify the bacterial distribution
Risk factors for slowly resolving pneumonia in the ICU 661and drug resistance in the ICU before choosing the proper
initial antibiotic therapy.
Different studies debate the use of steroids in pneu-
monia. Some studies found that corticosteroids exhibit
anti-inflammatory effects in severe pneumonia and enable
the rapid resolution of pneumonia.33,34 Other studies sug-
gested that steroids have adverse effects such as infection
and neuromuscular disease, which could delay pneumonia
resolution and increase mortality despite the use of an
appropriate antibiotic.35 In our study, in some patients the
pneumonia induced acute respiratory distress syndrome,
which required the administration of steroids to improve
oxygenation. Our study suggested that the administration
of high-dose steroids was related to SRP [relative risk (RR)
1.8462, 95% CI 1.5359e2.2191, p Z 0.0053]. However,
further investigation showed that the administration of
high-dose steroids was not an independent risk factor for
SRP, possibly because the sample size receiving high-dose
steroids was too small for a valid statistical analysis.
Our study has some limitations. First, this was a single-
center and retrospective study. A further prospective ran-
domized comparative study is warranted to prove that the
identification of high-risk patients can improve their
treatment outcomes. Because this was a retrospective
study, we had to analyze past information instead of adding
more tests to identify the pathogen. Second, some of the
trends observed might have reached statistical significance
if the study sample size had been larger. Third, the average
age of our population was 70.56  12.60 years, preventing
our results from properly reflecting the impact of age on
SRP.
In conclusion, SRP in critically ill patients should receive
more attention because of its high incidence, prolonged ICU
stays, and poor outcome. Treatment with an inappropriate
antibiotic, multilobar infiltration and a high CURB-65 score
were independent risk factors for SRP. The use of appro-
priate antibiotics in high-risk patients should be taken into
account to reduce the prevalence of SRP in the ICU.Conflicts of interest
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